Graduate School of Systemic Neurosciences GSN-LMU

Links and Functions

Breadcrumb Navigation

Marios Georgakis

Dr. Marios Georgakis

GSN associate faculty, GSN Alumnus


Clinician-Scientist, Junior Group Leader


Institute for Stroke and Dementia Research
Georgakis Lab
Feodor-Lynen-Straße 17
D-81377 München


Further Information

Keywords: cerebrovascular disease, stroke, atherosclerosis, cerebral small vessel disease, multi-omics, data science, epidemiology, population genetics

Research methods: bioinformatics population genetics genome-wide association studies Mendelian randomization multi-omics integration single-cell transcriptomics spatial transcriptomics machine learning epidemiological analyses meta-analysis

Brief research description: Cerebrovascular diseases, such as ischemic stroke, cerebral small vessel disease, intracerebral hemorrhage, and vascular dementia represent a leading cause of death and disability worldwide. My work is motivated by a pressing need to improve cerebrovascular health in the general population with the development of precise and personalized preventive and therapeutic strategies. To this end, my research group uses large-scale and multi-dimensional data from epidemiological studies and human biobanks (genomics, transcriptomics, proteomics, clinical data, and imaging) and applies innovative bioinformatic tools to inform such strategies. Our goals include: (i) the discovery and dissection of causal mechanisms contributing to cerebrovascular disease, (ii) the exploration of these mechanisms as potential targets for therapeutic and preventive strategies, (iii) the development of personalized risk stratification tools for patients with or at risk for cerebrovascular disease, and (iv) the development of accurate biomarkers that reflect disease activity and could be used to monitor disease progression and treatment response

Current GSN students: 

Selected publications:

1. Georgakis MK, Bernhagen J, Heitman L, Weber C, Dichgans M. Targeting the CCL2-CCR2 Axis for Atheroprotection: Triangulation of Evidence and Steps Towards Clinical Translation. Eur Heart J. 2022 May 14;43(19):1799-1808.

2. Mayerhofer E, Malik R, Parodi L, Burgess S, Harloff A, Dichgans M, Rosand J, Anderson CD, Georgakis MK. Genetically predicted on-statin LDL response is associated with higher intracerebral hemorrhage risk. Brain. 2022 Aug 27;145(8):2677-2686.

3. Georgakis MK, Parodi L, Frerich S, …, Anderson CD. Genetic architecture of stroke of undetermined source: overlap with known stroke etiologies and associations with modifiable risk factors. Ann Neurol. 2022 May;91(5):640-651.

4. Georgakis MK, Malik R, Li X, …, Dichgans M. Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association study. Circulation. 2021;143(11):1177-1180.

5. Georgakis MK, Gill D, Rannikmäe K, …, Dichgans M. Genetically Determined Levels of Circulating Cytokines and Risk of Stroke: Role of Monocyte Chemoattractant Protein-1. Circulation 2020;139(2):256-268.